EWA
HRTX icon

EverSource Wealth Advisors’s Heron Therapeutics HRTX Stock Holding History

EverSource Wealth Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$672 Buy
840
+199
+31% +$231 ﹤0.01% 3980
2025
Q4 		$833 Sell
641
-1,104
-63% -$1.36K ﹤0.01% 3757
2025
Q3 		$2.2K Buy
1,745
+1,550
+795% +$2.46K ﹤0.01% 3485
2025
Q2 		$404 Buy
195
+78
+67% +$159 ﹤0.01% 3950
2025
Q1 		$257 Buy
117
+84
+255% +$163 ﹤0.01% 3641
2024
Q4 		$50 Buy
+33
New +$53 ﹤0.01% 3637

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

EverSource Wealth Advisors's HRTX Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Heron Therapeutics (HRTX) stake by 31% in Q1 2026, buying an estimated $231 and bringing the position to 840 shares worth $672. The position accounts for ﹤0.01% of the portfolio, ranked #3980.

EverSource Wealth Advisors first reported a position in HRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.2K in Q3 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • EverSource Wealth Advisors held 840 shares of Heron Therapeutics worth $672 as of Q1 2026.
  • EverSource Wealth Advisors bought 199 Heron Therapeutics shares in Q1 2026, an estimated $231.
  • Heron Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3980 holding.
  • EverSource Wealth Advisors first reported a position in Heron Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • EverSource Wealth Advisors's Heron Therapeutics position peaked at $2.2K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.